Does Humana Cover Adderall? A Complete Insurance Guide

What Is Adderall and Why Does Coverage Get Complicated?

Adderall is a brand-name combination of mixed amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) approved by the FDA for attention-deficit/hyperactivity disorder (ADHD) in patients aged 3 and older, and for narcolepsy in patients aged 12 and older. The FDA first approved Adderall in 1996 and the extended-release formulation (Adderall XR) in 2001. Generic mixed amphetamine salts became widely available after 2010.

Why Schedule II Status Matters for Insurance

Because Adderall is a Schedule II controlled substance under the Controlled Substances Act, insurers apply additional administrative requirements that do not apply to most other medications. These include quantity limits per fill (typically a 30-day supply maximum), mandatory prescriber documentation of diagnosis, and, in many states, electronic prescribing requirements for controlled substances.

The Drug Enforcement Administration tightly regulates the supply chain for Schedule II stimulants. Shortages of amphetamine salts in 2022 and 2023 affected both availability and insurer formulary decisions, with some plans temporarily placing Adderall XR on non-formulary status. The FDA's shortage database remains the authoritative tracking resource for current supply status.

The Brand vs. Generic Distinction

Brand-name Adderall and Adderall XR carry substantially higher list prices than their generic counterparts. A 30-day supply of brand Adderall 20 mg carries a retail price exceeding $250 in most markets, while generic mixed amphetamine salts 20 mg averages under $50 at large-chain pharmacies. Humana, like most commercial and Medicare Part D insurers, places brand-name Adderall on Tier 4 or Tier 5 (non-preferred brand or specialty tier) while generic amphetamine salts sit at Tier 2 or Tier 3.

The FDA confirms that approved generic mixed amphetamine salts are bioequivalent to Adderall, meaning their rate and extent of absorption fall within the 80 to 125% bioequivalence window required for approval.

Does Humana Cover Generic Adderall (Amphetamine Salts)?

Generic mixed amphetamine salts are covered on most Humana commercial, Medicare Advantage, and standalone Part D plans. The answer for most members is yes, with conditions.

Commercial and Employer Plans

Humana's employer-sponsored commercial plans typically include generic amphetamine salts on their formulary at Tier 2 (preferred generic) or Tier 3 (non-preferred generic). A diagnosis of ADHD documented in the medical record is usually required. Copays for Tier 2 generics on Humana commercial plans range from roughly $10 to $30 per 30-day supply at in-network preferred pharmacies, though your specific Summary of Benefits and Coverage document controls the exact cost-sharing.

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline states: "For children ages 6 years and older, FDA-approved medications for ADHD are recommended, with the choice of medication based on comorbidities, patient and family preferences, and cost." The guideline is published in Pediatrics. Plans subject to the Mental Health Parity and Addiction Equity Act must apply the same prior authorization standards to ADHD medications as they do to comparable medical-surgical drugs.

Medicare Advantage and Part D Plans

Humana is one of the largest Part D sponsors in the United States. Generic amphetamine salts appear on the formularies of most Humana Medicare Advantage (MAPD) and standalone Prescription Drug Plans (PDP), generally at Tier 2 or Tier 3. CMS Part D formulary rules require plans to cover at least two drugs per therapeutic category, and stimulants for ADHD qualify as a protected category under many plan designs.

A specific caveat applies to Medicare beneficiaries: Medicare Part D did not cover Schedule II stimulants until the SUPPORT Act of 2018 removed the prior federal exclusion effective January 1, 2023. CMS confirmed that Part D plans may cover ADHD stimulants beginning plan year 2023. Humana updated its Part D formularies accordingly. However, individual plan documents still control whether your specific Humana PDP or MAPD includes the drug.

Medicaid Managed Care Plans

Humana also administers Medicaid managed care contracts in several states. State Medicaid programs set their own formulary rules. Most state Medicaid programs cover generic amphetamine salts for children and adults with an ADHD diagnosis, though some states impose additional step-therapy requirements (trying methylphenidate first). Check your state's preferred drug list (PDL) through your state Medicaid agency or Humana's Medicaid member portal.

Does Humana Cover Brand-Name Adderall?

Brand-name Adderall coverage through Humana is limited. Most Humana formularies list brand Adderall as non-formulary or place it at Tier 4 or Tier 5, meaning members pay the full non-preferred cost-sharing amount or the full retail price.

When Brand Coverage Is Possible

Three scenarios exist where Humana may approve brand Adderall:

1. Medical necessity exception. If your physician documents that you have failed generic amphetamine salts due to inactive ingredient sensitivity or a reproducible clinical difference, Humana's pharmacy department may grant a formulary exception placing brand Adderall at a lower cost-sharing tier.

2. Formulary exception request. Under CMS Part D rules, members have the right to request a formulary exception within 72 hours for a standard review or 24 hours for an expedited review if a delay would seriously harm health. 42 CFR 423.578 outlines these protections.

3. Employer plan design. Some self-insured employer plans administered by Humana include brand Adderall at a preferred tier if the employer negotiated that benefit design. Your Summary of Benefits and Coverage document is the controlling text.

The HealthRX pharmacy team uses the following decision framework when advising members on brand vs. Generic Adderall coverage appeals. Step 1: Confirm the exact formulary tier from Humana's Drug List tool using the specific plan ID. Step 2: Obtain a Letter of Medical Necessity from the prescribing clinician documenting any prior generic trial, outcomes, and rationale for brand. Step 3: Submit a formulary exception request through Humana's online portal or by calling the member services number on the back of the insurance card. Step 4: If denied at the plan level, file an Independent Review Organization (IRO) appeal within the timeframe printed on the denial notice.

How to Check Your Specific Humana Plan's Adderall Coverage

Formularies change annually. A drug covered in 2024 may move to a different tier or require new prior authorization in 2025.

Using Humana's Online Drug List Tool

Humana's Drug List (formulary search) tool at humana.com allows members to enter their plan ID and search for "amphetamine salts" or "Adderall" by name. The tool returns the current tier, any quantity limits, and any prior authorization or step-therapy requirements attached to that drug under your specific plan.

The FDA's Orange Book lists all FDA-approved amphetamine salt products and their generic equivalents, which is useful when confirming that a plan's generic substitution is therapeutically appropriate.

Reading Your Summary of Benefits and Coverage

The Summary of Benefits and Coverage (SBC) document, which insurers must provide under the Affordable Care Act, shows your drug benefit tiers and cost-sharing amounts. The SBC does not list individual drugs, so cross-reference it with the formulary document (also called the "Drug List" or "Prescription Drug Guide") that accompanies your plan materials each year.

Calling Humana Member Services

For controlled substances, pharmacy benefit questions are often resolved faster by calling the Pharmacy Benefits number on the back of your Humana ID card rather than through the general member services line. Ask specifically: "Is generic mixed amphetamine salts XR 20 mg on my formulary, what tier is it, and does it require prior authorization?"

Prior Authorization for Adderall: What Humana Requires

Prior authorization (PA) is a process by which Humana's pharmacy department reviews clinical documentation before approving coverage. Many Humana plans require PA for amphetamine salts, particularly at higher doses or for adults over 50.

Typical Documentation Requirements

Humana's PA criteria for stimulants generally include:

• A confirmed DSM-5 diagnosis of ADHD documented by a licensed clinician
• Age-appropriate screening or rating scale results (e.g., Conners Rating Scales, Adult ADHD Self-Report Scale)
• Documentation that a non-stimulant trial was considered or attempted (depending on plan)
• Prescribed dose falling within FDA-approved dosing ranges (Adderall IR: 5 to 60 mg/day for adults; Adderall XR: 5 to 30 mg/day for adults)

The FDA-approved labeling for mixed amphetamine salts is the reference document clinicians and payers use to evaluate whether a prescribed dose is within the approved range.

How Long PA Takes

Standard PA requests are typically processed within 1 to 3 business days. Expedited requests, which apply when a standard review timeline could seriously jeopardize health, must be resolved within 24 hours per CMS Part D rules and within the timeframe specified in your commercial plan's Evidence of Coverage document.

The American Academy of Neurology and the American Psychiatric Association have both published position statements opposing excessive prior authorization delays for psychiatric medications, noting that treatment gaps in ADHD management are associated with increased accident risk, occupational impairment, and relationship dysfunction.

What to Do If Humana Denies Adderall Coverage

A denial is not a final answer. Federal and state law provide a structured appeals process.

Step 1: Request a Coverage Determination

If your pharmacy tells you Adderall is not covered, ask your prescriber to submit a formal coverage determination request to Humana. This is different from the pharmacy simply running the claim; it is a written request for a coverage decision.

Step 2: File an Internal Appeal

If the coverage determination is denied, you have the right to file an internal appeal. For Medicare Part D plans, CMS requires that standard internal appeals be resolved within 7 days and expedited appeals within 72 hours.

Step 3: Request an Independent Review

If Humana upholds the denial at the internal appeal level, you can request review by an Independent Review Organization (IRO) contracted by CMS or your state insurance commissioner. CMS data from the 2022 Medicare Part D appeals report show that approximately 75% of Part D coverage determination cases decided at the IRO level are resolved in the enrollee's favor, which means appealing is statistically worthwhile.

Step 4: Contact Your State Insurance Commissioner

For commercial (non-Medicare) plans, state insurance departments regulate internal and external appeal timelines. Most states mandate external review decisions within 45 to 60 days for standard reviews and 72 hours for urgent reviews. The CMS External Appeals information page lists state-specific external review programs.

Cost Without Insurance or If Coverage Is Denied

If Humana denies coverage or the cost-sharing is prohibitive, several legitimate cost-reduction strategies exist.

GoodRx and Discount Programs

GoodRx and similar pharmacy discount platforms offer coupons for generic amphetamine salts that, in many markets, reduce the out-of-pocket price to $30, $60 for a 30-day supply. These discounts cannot be combined with insurance but are usable by anyone. The Federal Trade Commission has noted that pharmacy benefit manager practices can make insured prices higher than cash-pay discount prices at certain pharmacies, making it worth comparing both options at your specific pharmacy.

Manufacturer Patient Assistance Programs

Teva Pharmaceuticals, a major manufacturer of generic amphetamine salts, offers a patient assistance program for uninsured or underinsured patients. Eligibility criteria and enrollment are managed through NeedyMeds, an NIH-listed resource. Brand Adderall XR (Takeda) has historically offered a savings card for commercially insured patients, though these programs are not available to Medicare or Medicaid beneficiaries.

340B Program Pharmacies

Federally Qualified Health Centers and certain nonprofit hospitals participate in the 340B Drug Pricing Program, which allows them to purchase drugs at reduced prices and pass savings to qualifying patients. The HRSA 340B database lists participating covered entities by zip code.

ADHD, Adderall, and the Clinical Evidence Base

Understanding why Adderall is prescribed helps contextualize why coverage matters clinically.

Efficacy Data for Amphetamine Salts in ADHD

ADHD affects an estimated 8.1% of children aged 2 to 17 in the United States, per CDC prevalence data, and approximately 4.4% of adults. Stimulant medications including amphetamine salts are the most extensively studied pharmacological treatment for ADHD. A 2018 network meta-analysis published in The Lancet Psychiatry (Cortese et al., N=10,068 children and adolescents across 190 studies) found that amphetamines produced the largest effect size for reducing ADHD symptoms in children (standardized mean difference 0.79, 95% CI 0.62 to 0.97) compared with other stimulant and non-stimulant options.

A second analysis from the same research group covering 133 studies and 12,245 adults found amphetamines again produced the highest effect sizes for adult ADHD symptom reduction, with a standardized mean difference of 0.79 (95% CI 0.63 to 0.95) vs. Placebo. The findings are cited in the National Institute of Mental Health's ADHD treatment overview.

Safety Considerations That Affect Coverage Decisions

Payers, including Humana, apply quantity limits and prior authorization partly because of the documented cardiovascular risks of stimulants at high doses. The FDA added a boxed warning to amphetamine salt labeling noting high potential for abuse and dependence. A 2011 FDA-mandated review of cardiovascular events in new users of ADHD medications, published in the New England Journal of Medicine (Cooper et al., N=1,200,438 children and young adults), found no significant increase in serious cardiovascular events at typical therapeutic doses compared with non-use, providing some reassurance about safety at standard doses.

The FDA label specifies that Adderall IR adult dosing typically starts at 5 mg once or twice daily and is titrated upward based on response, with most adults reaching a therapeutic dose between 10 mg and 30 mg per day. Doses above 40 mg/day for adults are outside the labeled dosing range and virtually always trigger prior authorization from any insurer, including Humana.

Special Populations and Humana Coverage

Children and Adolescents

Humana commercial and Medicaid managed care plans generally cover generic amphetamine salts for children aged 6 and older when ADHD is documented. The AAP guideline cited above and the American Academy of Child and Adolescent Psychiatry (AACAP) 2020 practice parameter both support stimulant medication as a first-line treatment alongside behavioral therapy.

Adults Over 65 on Medicare

Medicare Part D coverage of ADHD stimulants for adults over 65 is newer (effective January 2023) and plans vary. Some Humana Part D plans require additional documentation of longstanding ADHD diagnosis for adults over 65, given that new-onset ADHD presentations in this age group warrant differential diagnosis to rule out other cognitive conditions. The American Geriatrics Society Beers Criteria lists stimulants as potentially inappropriate medications in older adults due to cardiovascular and appetite risks, which means some Humana Medicare plan medical directors apply additional scrutiny to these requests.

Pregnant Individuals

The FDA classifies amphetamine salts as Category C for pregnancy (older classification system) with known risks of premature birth and neonatal withdrawal. ACOG Practice Bulletin guidance on psychiatric medications in pregnancy recommends individualized risk-benefit discussions. Humana plans typically require additional documentation before covering stimulants during pregnancy.